Akari Therapeutics Plc (AKTX) stock
AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.70−0.81 (-12.44%)
Close on Nov 17, 2026Market cap $11.10MP/E –Yield –
Akari Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Akari Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $4.87M, up 69.7% year over year. For fiscal 2025 it was $2.82M, down 59.7% from the year before. Over ten years it grew -7.0% a year on average. The highest annual figure on record is $23.29M in fiscal 2017.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.82M | -59.7% |
| FY2024 | Dec 31, 2024 | $6.98M | +28.1% |
| FY2023 | Dec 31, 2023 | $5.45M | -43.0% |
| FY2022 | Dec 31, 2022 | $9.56M | +4.7% |
| FY2021 | Dec 31, 2021 | $9.13M | +3.6% |
| FY2020 | Dec 31, 2020 | $8.82M | +0.9% |
| FY2019 | Dec 31, 2019 | $8.74M | -25.9% |
| FY2018 | Dec 31, 2018 | $11.80M | -49.3% |
| FY2017 | Dec 31, 2017 | $23.29M | +34.6% |
| FY2016 | Dec 31, 2016 | $17.31M | +198.4% |
| FY2015 | Dec 31, 2015 | $5.80M | +258.8% |
| FY2014 | Dec 31, 2014 | $1.62M | +26.7% |
| FY2013 | Dec 31, 2013 | $1.28M | -14.0% |
| FY2012 | Dec 31, 2012 | $1.48M | +76.3% |
| FY2011 | Dec 31, 2011 | $841.00K | +240.5% |
| FY2010 | Dec 31, 2010 | $247.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.08M | +211.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.46M | +79.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.09M | -12.9% |
| Q3 FY2025 | Sep 30, 2025 | $249.00K | +74.1% |
| Q2 FY2025 | Jun 30, 2025 | $667.00K | -79.9% |
| Q1 FY2025 | Mar 31, 2025 | $813.00K | -64.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.25M | -50.3% |
| Q3 FY2024 | Sep 30, 2024 | $143.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $3.31M | +117.5% |
| Q1 FY2024 | Mar 31, 2024 | $2.28M | +31.7% |
| Q4 FY2023 | Dec 31, 2023 | $2.51M | -12.0% |
| Q3 FY2023 | Sep 30, 2023 | -$314.00K | -114.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.52M | -49.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.73M | -51.8% |
| Q2 FY2022 | Jun 30, 2022 | $2.85M | -44.3% |
| Q2 FY2021 | Jun 30, 2021 | $2.18M | -42.3% |
| Q2 FY2020 | Jun 30, 2020 | $3.02M | -44.5% |
| Q2 FY2019 | Jun 30, 2019 | $3.59M | +139.6% |
| Q2 FY2018 | Jun 30, 2018 | $5.12M | +165.4% |
| Q2 FY2017 | Jun 30, 2017 | $3.78M | +188.0% |
| Q2 FY2016 | Jun 30, 2016 | $5.44M | +443.7% |
| Q1 FY2016 | Mar 31, 2016 | $1.50M | -3.6% |
| Q4 FY2015 | Dec 31, 2015 | $1.93M | +79.3% |
| Q3 FY2015 | Sep 30, 2015 | $1.31M | +707.8% |
| Q2 FY2015 | Jun 30, 2015 | $1.00M | -35.0% |
| Q1 FY2015 | Mar 31, 2015 | $1.55M | – |
| Q4 FY2014 | Dec 31, 2014 | $1.08M | – |
| Q3 FY2014 | Sep 30, 2014 | $162.58K | – |
| Q2 FY2014 | Jun 30, 2014 | $1.54M | – |
See a number that looks wrong?